Angiotensin-converting enzyme inhibitor (ACE inhibitors) drugs include Benazepril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik).
To report any serious adverse events associated with the use of these drugs, please contact the FDA MedWatch program using the contact information at the bottom of this page.
FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)
Information for Healthcare Professionals: Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor) Drugs and Pregnancy[ARCHIVED]
FDA Alert (6/2006)
Public Health Advisory: Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor) Drugs and Pregnancy[ARCHIVED]
FDA Public Health Advisory (6/7/2006)
Labeling and Regulatory History from Drugs@FDA
Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor) Drugs
Regulatory History of Lotensin and Labeling Information Benazepril (marketed as Lotensin) Regulatory History of Capoten Captopril (marketed as Capoten) Regulatory History of Vasotec and Labeling Information Enalapril/Enalaprilat (marketed as Vasotec oral and injectable) Regulatory History of Monopril and Labeling Information Fosinopril (marketed as Monopril) Regulatory History of Zestril and Labeling Information Lisinopril (marketed as Zestril) Regulatory History of Prinivil and Labeling Information Lisinopril (marketed as Prinivil) Regulatory History of Univasc Moexipril (marketed as Univasc) Regulatory History of Aceon and Labeling Information Perindopril (marketed as Aceon) Regulatory History of Accupril Quinapril (marketed as Accupril) Regulatory History of Altace Ramipril (marketed as Altace) Regulatory History of Mavik Trandolapril (marketed as Mavik)